Risk of cataract in patients treated with statins

Archives of Internal Medicine

Volumn 161, Issue 16, 2001, Pages 2021-2026

  Schlienger, Raymond G ^a,b   Haefeli, Walter E ^c   Jick, Hershel ^d   Meier, Christoph R ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; CORTICOSTEROID;

ADULT; AGED; ARTICLE; CATARACT; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; ANAMNESIS; CATARACT EXTRACTION; DATA BASE; DRUG EFFECT; DRUG RESPONSE; DRUG USE; PRESCRIPTION; RISK FACTOR; UNITED KINGDOM;

EID: 0035955906     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.16.2021     Document Type: Article

References (40)

1. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
3. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
4. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors
5. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors
6. The safety evaluation of fluvastatin, an HMG-CoA reductase inhibitor, in beagle dogs and rhesus monkeys
7. Cataracte et simvastatine: À propos d'un cas
8. Pravastatin: Ocular side effects after a two year follow-up?
9. Long-term safety and efficacy profile of simvastatin
10. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study
11. The human lens after 48 weeks of treatment with lovastatin
12. HMG-CoA reduktasehemmer simvastatin und pravastatin: Kein hinweis für nebenwirkungen am auge bei anwendungen am menschen
13. Ocular drug safety and HMG-CoA reductase inhibitors
14. Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia
15. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
16. A database worth saving
17. The UK general practice research database
18. Use of the UK general practice research database for pharmacoepidemiology
19. HMG-CoA reductase inhibitors and the risk of fractures
20. Risk of cataract among users of intranasal corticosteroids
21. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom
22. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom
23. Risk factors for age-related cataracts
24. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
25. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
26. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
27. Atorvastatin is not cataractogenic in beagle dogs
28. Long term oral administration study of pravastatin sodium to beagles for 104 weeks
29. Medications and cataract: The Blue Moutains Eye Study
30. Animal safety and toxicology of simvastatin and related hydroxy-methyglutaryl coenzyme A reductase inhibitors
31. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
32. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s
33. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
34. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
35. Rhabdomyolysis induced by simvastatin and ketoconazole treatment
36. Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
37. Biotransformation of pravastatin sodium in humans
38. Association of inhaled corticosteroid use with cataract extraction in elderly patients
39. Use of inhaled corticosteroids and the risk of cataracts
40. Cholesterol and cataracts